453 related articles for article (PubMed ID: 30744686)
21. Barriers to and Facilitators of Alcohol Use Disorder Pharmacotherapy in Primary Care: A Qualitative Study in Five VA Clinics.
Williams EC; Achtmeyer CE; Young JP; Berger D; Curran G; Bradley KA; Richards J; Siegel MB; Ludman EJ; Lapham GT; Forehand M; Harris AHS
J Gen Intern Med; 2018 Mar; 33(3):258-267. PubMed ID: 29086341
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological treatment of alcohol dependence: a review of the evidence.
Garbutt JC; West SL; Carey TS; Lohr KN; Crews FT
JAMA; 1999 Apr; 281(14):1318-25. PubMed ID: 10208148
[TBL] [Abstract][Full Text] [Related]
23. Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder.
Burnette EM; Nieto SJ; Grodin EN; Meredith LR; Hurley B; Miotto K; Gillis AJ; Ray LA
Drugs; 2022 Feb; 82(3):251-274. PubMed ID: 35133639
[TBL] [Abstract][Full Text] [Related]
24. Primary Care Providers' Interest in Using a Genetic Test to Guide Alcohol Use Disorder Treatment.
Williams EC; Young JP; Achtmeyer CE; Hendershot CS
J Subst Abuse Treat; 2016 Nov; 70():14-20. PubMed ID: 27692183
[TBL] [Abstract][Full Text] [Related]
25. Selecting an appropriate alcohol pharmacotherapy: review of recent findings.
Castrén S; Mäkelä N; Alho H
Curr Opin Psychiatry; 2019 Jul; 32(4):266-274. PubMed ID: 30973369
[TBL] [Abstract][Full Text] [Related]
26. Rates of prescription orders for United States active duty service members diagnosed with alcohol use disorder.
Peters ZJ; Kincaid MW; Greenberg JG; Quah RF; Curry JC
Subst Abus; 2021; 42(4):638-645. PubMed ID: 32870103
[No Abstract] [Full Text] [Related]
27. Prescription procedures in medication for relapse prevention after inpatient treatment for alcohol use disorders in Switzerland.
Buri C; Moggi F; Giovanoli A; Strik W
Alcohol Alcohol; 2007; 42(4):333-9. PubMed ID: 17517820
[TBL] [Abstract][Full Text] [Related]
28. Pharmacotherapy of alcohol use disorders in the Veterans Health Administration.
Harris AH; Kivlahan DR; Bowe T; Humphreys KN
Psychiatr Serv; 2010 Apr; 61(4):392-8. PubMed ID: 20360279
[TBL] [Abstract][Full Text] [Related]
29. Medication Development for Alcohol Use Disorder: A Focus on Clinical Studies.
Leggio L; Falk DE; Ryan ML; Fertig J; Litten RZ
Handb Exp Pharmacol; 2020; 258():443-462. PubMed ID: 31628604
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological interventions for alcohol misuse in correctional settings: A systematic review.
Slavin-Stewart C; Minhas M; Turna J; Brasch J; Olagunju AT; Chaimowitz G; MacKillop J
Alcohol Clin Exp Res; 2022 Jan; 46(1):13-24. PubMed ID: 34825363
[TBL] [Abstract][Full Text] [Related]
31. Trends in the Use of Naltrexone for Addiction Treatment among Alcohol Use Disorder Admissions in U.S. Substance Use Treatment Facilities.
Qeadan F; Mensah NA; Gu LY; Madden EF; Venner KL; English K
Int J Environ Res Public Health; 2021 Aug; 18(16):. PubMed ID: 34444639
[TBL] [Abstract][Full Text] [Related]
32. Effects of a multifaceted implementation intervention to increase utilization of pharmacological treatments for alcohol use disorders in the US Veterans Health Administration.
Harris AHS; Brown R; Dawes M; Dieperink E; Myrick DH; Gerould H; Wagner TH; Wisdom JP; Hagedorn HJ
J Subst Abuse Treat; 2017 Nov; 82():107-112. PubMed ID: 29021108
[TBL] [Abstract][Full Text] [Related]
33. Review of Evidence-Based Strategies to Treat Alcohol Use Disorder.
Worley J
J Psychosoc Nurs Ment Health Serv; 2021 Dec; 59(12):7-11. PubMed ID: 34846245
[TBL] [Abstract][Full Text] [Related]
34. Influence of comorbid drug use disorder on receipt of evidence-based treatment for alcohol use disorder among VA patients with alcohol use disorder and Hepatitis C and/or HIV.
Frost MC; Matson TE; Tsui JI; Williams EC
Drug Alcohol Depend; 2019 Jan; 194():288-295. PubMed ID: 30469100
[TBL] [Abstract][Full Text] [Related]
35. Predictors of initiation of and retention on medications for alcohol use disorder among people living with and without HIV.
Oldfield BJ; McGinnis KA; Edelman EJ; Williams EC; Gordon AJ; Akgün K; Crystal S; Fiellin LE; Gaither JR; Goulet JL; Korthuis PT; Marshall BDL; Justice AC; Bryant K; Fiellin DA; Kraemer KL
J Subst Abuse Treat; 2020 Feb; 109():14-22. PubMed ID: 31856946
[TBL] [Abstract][Full Text] [Related]
36. Medications for Alcohol Use Disorder.
Poorman E; McQuade BM; Messmer S
Am Fam Physician; 2024 Jan; 109(1):71-78. PubMed ID: 38227873
[TBL] [Abstract][Full Text] [Related]
37. Patient perspectives on alcohol use disorder pharmacotherapy and integration of treatment into primary care settings.
Haley SJ; Pinsker EA; Gerould H; Wisdom JP; Hagedorn HJ
Subst Abus; 2019; 40(4):501-509. PubMed ID: 30829127
[No Abstract] [Full Text] [Related]
38. Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence.
Baser O; Chalk M; Rawson R; Gastfriend DR
Am J Manag Care; 2011 Jun; 17 Suppl 8():S222-34. PubMed ID: 21761948
[TBL] [Abstract][Full Text] [Related]
39. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate.
Palpacuer C; Duprez R; Huneau A; Locher C; Boussageon R; Laviolle B; Naudet F
Addiction; 2018 Feb; 113(2):220-237. PubMed ID: 28940866
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
